Department of Surgery, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Obes Surg. 2012 Dec;22(12):1903-8. doi: 10.1007/s11695-012-0774-1.
Sleeve gastrectomy (SG) is an upcoming primary treatment modality for morbid obesity. The aim of this study was to report the indications for and the outcomes of revisional surgery after SG.
Four hundred sixteen individuals underwent a SG between August 2006 and July 2010 with a minimum follow-up of 12 months. The patients that needed revision were identified from our prospective registry. Patients were subdivided in a first group undergoing revision as part of a two-step procedure, a second group with failure of a secondary SG, and a third group with failure of a primary SG.
Twenty-three patients (5.5%) had an unplanned revision. Fourteen (3.4%) had a two-step procedure because of super obesity. A significant additional weight loss was achieved after revision; no complications occurred in this group. Five patients with failure of a secondary SG had no significant additional weight loss after revision. Reflux disease was cured. Eighteen patients in the third group showed significant additional weight loss and remission of diabetes and hypertension. Both reflux disease and dysphagia did not heal in all affected patients after revision. The early complication rate in the whole cohort was 23.4%; staple line leakage was 5.4%, and bleeding was 8.1%. Revision-related mortality was 0%.
In a large series of sleeve gastrectomies, the unplanned revision rate was 5.5%. Revision of a sleeve gastrectomy is feasible in patients that do not achieve sufficient weight loss and in those patients developing complications after the initial sleeve gastrectomy.
袖状胃切除术(SG)是治疗病态肥胖的新兴主要治疗方法。本研究的目的是报告 SG 后再次手术的适应证和结果。
416 名患者于 2006 年 8 月至 2010 年 7 月期间接受了 SG,随访时间至少为 12 个月。从我们的前瞻性登记册中确定了需要修正的患者。将患者分为三组:第一组作为两步手术的一部分进行修正,第二组是二次 SG 失败,第三组是初次 SG 失败。
23 名患者(5.5%)进行了非计划修订。14 例(3.4%)因超级肥胖而进行了两步手术。修订后实现了显著的额外减重,该组无并发症发生。5 例二次 SG 失败的患者在修正后没有显著的额外减重。反流性疾病得到治愈。第三组的 18 名患者在减重和糖尿病、高血压缓解方面取得了显著的额外效果。所有受影响的患者在修订后反流性疾病和吞咽困难都没有治愈。整个队列的早期并发症发生率为 23.4%;吻合口漏发生率为 5.4%,出血发生率为 8.1%。与修订相关的死亡率为 0%。
在大规模的袖状胃切除术系列中,非计划修订率为 5.5%。对于未达到足够减重效果和在初次袖状胃切除术后出现并发症的患者,可对袖状胃切除术进行修正。